These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29017824)

  • 1. Early postoperative intraperitoneal chemotherapy is associated with survival benefit for appendiceal adenocarcinoma with peritoneal dissemination.
    Huang Y; Alzahrani NA; Liauw W; Soudy H; Alzahrani AM; Morris DL
    Eur J Surg Oncol; 2017 Dec; 43(12):2292-2298. PubMed ID: 29017824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial?
    Huang Y; Alzahrani NA; Liauw W; Traiki TB; Morris DL
    Ann Surg Oncol; 2017 Jan; 24(1):176-183. PubMed ID: 27718032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
    Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
    Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
    Kozman MA; Fisher OM; Rebolledo BJ; Valle SJ; Alzahrani N; Liauw W; Morris DL
    Eur J Surg Oncol; 2017 Dec; 43(12):2299-2307. PubMed ID: 28993033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix.
    Sparks DS; Morris B; Xu W; Fulton J; Atkinson V; Meade B; Lutton N
    Int Surg; 2015 Jan; 100(1):21-8. PubMed ID: 25594636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours.
    Ansari N; Chandrakumaran K; Dayal S; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2016 Jul; 42(7):1035-41. PubMed ID: 27132072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases.
    Ihemelandu C; Mavros MN; Sugarbaker P
    Ann Surg Oncol; 2016 Dec; 23(13):4231-4237. PubMed ID: 27338748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of perioperative intraperitoneal chemotherapy regimen in appendiceal and colorectal peritoneal carcinomatosis.
    Chua TC; Liauw W; Zhao J; Morris DL
    Int J Clin Oncol; 2013 Jun; 18(3):439-46. PubMed ID: 22415741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological Subtype Remains a Significant Prognostic Factor for Survival Outcomes in Patients With Appendiceal Mucinous Neoplasm With Peritoneal Dissemination.
    Huang Y; Alzahrani NA; Chua TC; Morris DL
    Dis Colon Rectum; 2017 Apr; 60(4):360-367. PubMed ID: 28267002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extensive surgical history prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with poor survival outcomes in patients with peritoneal mucinous carcinomatosis of appendiceal origin.
    Milovanov V; Sardi A; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
    Eur J Surg Oncol; 2015 Jul; 41(7):881-5. PubMed ID: 25899982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal Spread of Low-grade Appendiceal Tumours - 2 Days of Early Postoperative Intra-peritoneal Chemotherapy Are Enough.
    Rao A; Mui J; Barat S; Matar AA; Alzahrani N; Morris DL
    Anticancer Res; 2021 Nov; 41(11):5569-5575. PubMed ID: 34732427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early postoperative intraperitoneal chemotherapy (EPIC) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in 632 patients with pseudomyxoma peritonei of appendiceal origin: A single institution experience.
    Fung X; Li IC; Chandrakumaran K; Cecil T; Dayal S; Tzivanakis A; Moran B; Mohamed F
    Eur J Surg Oncol; 2022 Jul; 48(7):1614-1618. PubMed ID: 35168851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis.
    El Halabi H; Gushchin V; Francis J; Athas N; Macdonald R; Nieroda C; Studeman K; Sardi A
    Ann Surg Oncol; 2012 Jan; 19(1):110-4. PubMed ID: 21701929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
    Tan GH; Ong WS; Chia CS; Tham CK; Soo KC; Teo MC
    Int J Hyperthermia; 2016 May; 32(3):281-8. PubMed ID: 26862667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
    J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.